Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases

Next Previous
X
Search
Trial Profile

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary) ; Hyaluronidase; Immune globulin
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions
  • Sponsors Baxalta; Shire; Takeda

    • Most Recent Events

    • 04 Dec 2021 This trial has been completed in Greece, according to European Clinical Trials Database record. (Global end date:15 Jan 2021)
    • 19 Feb 2021 This trial has been completed in France, according to European Clinical Trials Database record. (Global end date:15 Jan 2021)
    • 18 Feb 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top